Matthias Will
Chief Development Officer Autolus
Matthias Will serves as Autolus’ Chief Development Officer. Previously, he served as Chief Medical Officer at Dren Bio, Inc., where he led the expansion of the clinical team and oversaw the submission of two INDs for hematologic cancer candidates. Prior to that, he was Vice President of Clinical Development at CRISPR Therapeutics, leading allogeneic CAR T programs targeting CD70 and an early-stage CD70-NK program. He also led clinical development at CytomX Therapeutics and held senior roles at Gilead Sciences and Novartis Oncology. Dr. Will earned his M.D. from Hannover Medical School and trained in hematology and oncology at the University of Tübingen.
Seminars
Wednesday 16th September 2026
Evolving CAR-T Therapies to Shift Beyond Hematological Malignancies
12:10 pm
- Comparing PK profiles in autoimmune diseases and hematological malignancies to uncover differences in exposure, persistence, and dosing strategies
- Highlighting how endpoints, patient selection, and lymphodepletion approaches differ in lupus and MS
- Exploring clinical safety data to enhance autologous CAR-T expansions beyond oncology
